Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, markets, and exports pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, other European countries, the Middle East, Latin America, and internationally. More Details
Adequate balance sheet and fair value.
Share Price & News
How has Wockhardt Bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: Insufficient data to determine WBIO's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine WBIO's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how WBIO performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how WBIO performed against the Swiss Market.
Long-Term Price Volatility Vs. Market
How volatile is Wockhardt Bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StAre Wockhardt Bio's (BRN:WBIO) Statutory Earnings A Good Guide To Its Underlying Profitability?
5 months ago | Simply Wall StWockhardt Bio (BRN:WBIO) Has Debt But No Earnings; Should You Worry?
11 months ago | Simply Wall StDoes Wockhardt Bio (BRN:WBIO) Have A Healthy Balance Sheet?
Is Wockhardt Bio undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate WBIO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate WBIO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: WBIO is good value based on its PE Ratio (6.8x) compared to the XE Biotechs industry average (43.3x).
PE vs Market: WBIO is good value based on its PE Ratio (6.8x) compared to the Swiss market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: WBIO is good value based on its PB Ratio (0.7x) compared to the CH Biotechs industry average (3x).
How is Wockhardt Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wockhardt Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Wockhardt Bio is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Wockhardt Bio competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Wockhardt Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WBIO has high quality earnings.
Growing Profit Margin: WBIO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: WBIO's earnings have declined by 35.2% per year over the past 5 years.
Accelerating Growth: WBIO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: WBIO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).
Return on Equity
High ROE: WBIO's Return on Equity (9.7%) is considered low.
How is Wockhardt Bio's financial position?
Financial Position Analysis
Short Term Liabilities: WBIO's short term assets ($315.2M) exceed its short term liabilities ($294.4M).
Long Term Liabilities: WBIO's short term assets ($315.2M) exceed its long term liabilities ($100.1M).
Debt to Equity History and Analysis
Debt Level: WBIO's debt to equity ratio (81.8%) is considered high.
Reducing Debt: WBIO's debt to equity ratio has increased from 68.7% to 81.8% over the past 5 years.
Debt Coverage: WBIO's debt is well covered by operating cash flow (24.8%).
Interest Coverage: WBIO's interest payments on its debt are well covered by EBIT (3.6x coverage).
What is Wockhardt Bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: WBIO is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WBIO's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Wockhardt Bio has no CEO, or we have no data on them.
|MD & Director||13yrs||US$713.77k||0.049% |
|Chairman of the Board||1.75yrs||US$30.00k||no data|
|Director||1.33yrs||no data||no data|
Experienced Board: WBIO's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Wockhardt Bio AG's company bio, employee growth, exchange listings and data sources
- Name: Wockhardt Bio AG
- Ticker: WBIO
- Exchange: BRSE
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF149.091m
- Shares outstanding: 51.95m
- Website: https://www.wockhardtbio.com
- Wockhardt Bio AG
- Grafenauweg 6
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|WBIO||BRSE (Berne Stock Exchange)||Yes||Bearer Shares||CH||CHF||Dec 2013|
Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, markets, and exports pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 19:57|
|End of Day Share Price||2021/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.